Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$1.66 USD

1.66
5,229,657

-0.08 (-4.32%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $1.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Indrajit Bandyopadhyay headshot

U.S. Market Faces Worst Meltdown Since 2020: Here's Why

Major U.S. indices nosedived on Sep 14 following the inflation report for the month of August.

PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag

PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.

Can Pacific Biosciences (PACB) Climb 261% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 261.4% upside potential for Pacific Biosciences (PACB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Inogen (INGN) Surges 5.1%: Is This an Indication of Further Gains?

Inogen (INGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PacBio's (PACB) Q1 Earnings Miss Estimates, Revenues Beat

PacBio (PACB) sees strength in Q1 segmental revenues, led by robust consumable and instrument sales.

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -15.63% and 1.29%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Should You Buy?

Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LHC Group (LHCG) Ties Up to Improve Home Health Services

LHC Group's (LHCG) latest joint venture with Archbold Medical Center to enhance home health services in Thomasville and across South Georgia.

Illumina (ILMN) Invests in Seven Additional Genomics Startups

Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.

Why Is Pacific Biosciences (PACB) Down 13.6% Since Last Earnings Report?

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PacBio (PACB) Supports SickKids With Sequencing Technology

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.

PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Debanjana Dey headshot

Medical Device Stocks Earnings on Feb 2: IDXX, ABC & ALGN

The Medical Device companies' Q4 results are likely to reflect base business recovery. Let's see how IDXX, ABC, and ALGN are poised ahead of their earnings releases.

DaVita's (DVA) Collaboration to Aid in Kidney Care Needs

DaVita's (DVA) work with transplant providers and kidney doctors is likely to slow CKD progression and bolster access to home dialysis and kidney transplantation.

PacBio (PACB) to Leverage Google's Deep Learning Technologies

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues

PacBio's (PACB) solid fourth-quarter results are likely to have been boosted by strong segmental performances and robust placement of Sequel systems.

Company News for Jan 12, 2022

Companies in The News Are: ACCD,PACB,BIG,ILMN

PacBio's (PACB) Sequel IIe Boosts Radboudumc's Sequencing Ability

PacBio's (PACB) sequencing system enhances Radboudumc's SMRT sequencing capability through the addition of two new PacBio Sequel IIe systems.

PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada

PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.

PacBio's (PACB) New Surveillance Kit Successful Against Omicron

PacBio's (PACB) latest surveillance kit is expected to aid public health entities to better answer critical questions about Omicron and its impacts.

Kevin Cook headshot

Bull of the Day: Mesa Laboratories (MLAB)

Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy

PacBio (PACB)-UCLA Health Tie Up for Rare Diseases' WGS Research

PacBio's (PACB) latest research collaboration is expected to identify the causes behind rare diseases and provide more effective treatments.